Search hospitals > Florida > Jacksonville
Nemours Childrens Clinic
Claim this profileJacksonville, Florida 32207
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Brain Tumor
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Lymphoma
418 reported clinical trials
9 medical researchers
Summary
Nemours Childrens Clinic is a medical facility located in Jacksonville, Florida. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Brain Tumor, Acute Lymphoblastic Leukemia, Lymphoma and other specialties. Nemours Childrens Clinic is involved with conducting 418 clinical trials across 531 conditions. There are 9 research doctors associated with this hospital, such as Scott M. Bradfield, Ramamoorthy Nagasubramanian, Emi H. Caywood, and Kathryn Blake, PharmD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Adult T-Cell Leukemia/Lymphoma
Global LeaderStage II
NTRK1 positive
NTRK positive
Top PIs
Scott M. BradfieldAlfred I duPont Hospital for Children8 years of reported clinical research
Expert in Brain Tumor
Expert in Cancer
45 reported clinical trials
81 drugs studied
Ramamoorthy NagasubramanianNemours Children's Clinic-Jacksonville4 years of reported clinical research
Expert in Cancer
Studies Neuroblastoma
28 reported clinical trials
62 drugs studied
Emi H. CaywoodAlfred I duPont Hospital for Children6 years of reported clinical research
Expert in Adult T-Cell Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
23 reported clinical trials
63 drugs studied
Kathryn Blake, PharmDNemours Children's Health System3 years of reported clinical research
Studies Stress Prevention
Studies Acute Pain
6 reported clinical trials
6 drugs studied
Clinical Trials running at Nemours Childrens Clinic
Acute Lymphoblastic Leukemia
Brain Tumor
Cancer
Testicular cancer
Adult T-Cell Leukemia/Lymphoma
Wilms Tumor
Testicular Carcinoma
Lymphoid Hematopoietic Disease
Germ Cell Tumors
Ovarian Carcinoma
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Blinatumomab + Dasatinib/Imatinib
for Acute Lymphoblastic Leukemia
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.
Recruiting2 awards Phase 35 criteria
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Nemours Childrens Clinic?
Nemours Childrens Clinic is a medical facility located in Jacksonville, Florida. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Brain Tumor, Acute Lymphoblastic Leukemia, Lymphoma and other specialties. Nemours Childrens Clinic is involved with conducting 418 clinical trials across 531 conditions. There are 9 research doctors associated with this hospital, such as Scott M. Bradfield, Ramamoorthy Nagasubramanian, Emi H. Caywood, and Kathryn Blake, PharmD.
Where is Nemours Childrens Clinic located?
**Nemours Children's Clinic, Jacksonville, FL**
- **Address:** 4600 Touchton Rd E, Jacksonville, FL 32246
- **Services:** For convenient scheduling, viewing test results, and more, use the Nemours app.
Who should I call to ask about financial aid or insurance network?
Nemours Children's Clinic offers financial assistance and insurance support. For assistance, contact their financial department at (844) 551-2065 or for billing inquiries, call customer service at (866) 390-3610, available Monday through Friday, 8 a.m. to 4 p.m. EST. The Nemours Financial Assistance Program (NFAP) provides care at discounted rates or for free to eligible patients, with eligibility based on 250% to 300% of the Federal Poverty Level Guidelines.
What insurance does Nemours Childrens Clinic accept?
Nemours Children's Health accepts a variety of insurance plans. For detailed information on specific insurance plans accepted at the Nemours Children's Clinic location, please contact the clinic directly or visit their official website.
What awards or recognition has Nemours Childrens Clinic received?
Nemours Children's Clinic in Jacksonville, Florida, is a recipient of significant funding from the National Institutes of Health (NIH), including a recent NIH R01 grant. The clinic collaborates with prestigious institutions such as Wolfson Children's Hospital, University of Florida Health Jacksonville, and Mayo Clinic Jacksonville for clinical research studies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.